Daniel Henning


Dr. Henning recently received funding for two new studies he is working on. The first, titled Early identification of SEPsis SIGN in emergency department, is seeking to validate the prognostic performances in addition to clinical signs and symptoms of sVEGFR2 alone or in combination with other biomarkers (PCT, suPAR) or in combination with clinical parameters to ruling-out clinical deterioration of non-severe patients with suspected infection in ED over a 72-hour period after their inclusion.

The second study that Dr. Henning received funding for is titled Innovative Methods to Evaluate the Role of Influenza Vaccines in Attenuating Severe Disease in Adults - IVY‐2021 Surveillance Study and is sponsored by the CDC. This study is a multicenter prospective observational public health surveillance activity designed to monitor acute respiratory infections in adults caused by influenza and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).  The key objectives include monitoring vaccine effectiveness for influenza vaccines; monitoring the severity of illness caused by influenza and SARS-CoV-2; and identifying patients at highest risk for clinical decompensation, including the development of paradigms for sub-phenotyping critical illness from influenza and SARS-CoV-2 infections.